|
EQS-Ad-hoc: Alzchem Group AG / Key word(s): Expansion/Strategic Company Decision Trostberg, October 2, 2024 – Alzchem Group AG plans significantly increase its production capacity for nitroguanidine. It was only in spring of this year that the company announced a capacity expansion for the preliminary stage with an investment of EUR 76 million over several years. Taking into account the additional expansion plans for a new production plant, the total investment will almost double. Alzchem expects this to result in increasing revenues in the upper double-digit million range from 2027 onwards, with correspondingly positive contributions to earnings. To this end, supply contracts have already been signed with several customers in the defense sector, who have declared their willingness to make significant contributions to the financing of the new plant in the common interest. The new production capacities are expected to be commissioned in the second half of 2026.
As part of this investment, the largest in the company’s history, Alzchem will not only build a new nitroguanidine production plant but also renew and expand the existing facilities for the production of guanidine nitrate, the precursor of nitroguanidine. For this first investment project, the company was already awarded an investment grant of EUR 34.4 million by the EU Commission in March of this year as part of the ASAP (“Act in Support of Ammunition Production”) funding instrument (see ad hoc announcement dated March 15, 2024). In parallel to the measures in Germany, Alzchem will intensify its site search in the USA. To this end, a preliminary contract has been concluded with the US Department of Defense that extends over the next two years. In the event that a suitable production site is found during this period, the US Department of Defense has already committed USD 150 million in funding for the construction of a production facility in the US by the end of 2029. End of Inside Information
02-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Alzchem Group AG |
| Dr.-Albert-Frank-Str. 32 | |
| 83308 Trostberg | |
| Germany | |
| Phone: | +498621862888 |
| Fax: | +49862186502888 |
| E-mail: | ir@alzchem.com |
| Internet: | www.alzchem.com |
| ISIN: | DE000A2YNT30 |
| WKN: | A2YNT3 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
| EQS News ID: | 2000651 |
| End of Announcement | EQS News Service |
|
|
2000651 02-Oct-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
